Photodynamic Therapy Market by Type (Photosensitizer Drugs and Devices), By Technology (Cancer, Acne, Psoriasis, Actinic Keratosis and Other Application), and By Application (Hospitals, Cosmetics & Dermatology Clinics, Cancer Treatment Centers and Research Institutions), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

The Global Photodynamic Therapy Market Size is expected to be worth around US$ 10.1 Billion by 2034, from US$ 4.8 Billion in 2024, growing at a CAGR of 7.6% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 36.1% share and holds US$ 1.7 Billion market value for the year.

Photodynamic Therapy Market, Global Analysis, 2020-2024 (US$ Billion)

The Photodynamic Therapy (PDT) market is experiencing significant growth, driven by the rising incidence of cancer, advancements in medical technologies, and increased awareness of non-invasive treatment options. PDT utilizes light-sensitive drugs (photosensitizers) activated by specific light wavelengths to target and destroy abnormal cells, offering a precise and minimally invasive alternative to traditional therapies. It is particularly gaining popularity in oncology, especially for treating skin cancer, due to its precision and reduced side effects.

• According to WHO, in 2022, there were nearly 20 million new cancer cases and 9.7 million deaths.
• According to the ACS Journal in 2024, the United States was projected to witness 2,001,140 new cancer cases. Additionally, 611,720 cancer-related deaths were expected to occur. These figures highlight the growing burden of cancer in the country.

Technological innovations have greatly enhanced the PDT market. Improvements in light sources, such as lasers and LED systems, have increased light penetration accuracy and treatment effectiveness. Additionally, the development of new photosensitizers with enhanced targeting abilities and fewer side effects has expanded PDT’s applications, making it a more versatile treatment option.

Rising awareness among patients and healthcare providers about the benefits of PDT is another key driver of market growth. Educational initiatives and campaigns by healthcare organizations have emphasized PDT’s advantages, including reduced recovery times and minimal invasiveness, leading to increased acceptance and usage. However, the high cost of PDT, driven by expensive photosensitizers and advanced light equipment, remains a significant barrier to widespread adoption, especially in low-income areas. Addressing these cost challenges is crucial for making PDT more accessible.

Despite these obstacles, the market continues to expand, fueled by ongoing innovation and strategic partnerships between industry leaders. The introduction of new products, such as advanced photosensitizers and light-based devices, is improving treatment outcomes and expanding PDT’s applications. Recent regulatory approvals for new PDT drugs and devices have further strengthened the market by boosting credibility and promoting broader adoption.

• In December 2023, the US Patent Office (USPTO) accepted Biofrontera AG’s patent application for a novel lighting technique in PDT, which covers innovations in the treatment of dermatological skin disorders.

Key Takeaways

• The Photodynamic Therapy market generated a revenue of US$ 4.82 Billion and is predicted to reach US$ 10.1 Billion, with a CAGR of 7.6%.
• Based on the Type, the Photosensitizer Drugs segment generated the most revenue for the market with a market share of 75.4%.
• Based on the Technology, the Cancer segment generated the most revenue for the market with a market share of 42.9%.
• Based on the Application, the Hospitals segment generated the most revenue for the market with a market share of 48.5%.
• Region-wise, North America remained the lead contributor to the market, by claiming the highest market share, amounting to 36.1%.

Type Analysis

The Photodynamic Therapy (PDT) market is segmented by type into photosensitizer drugs and devices, with photosensitizer drugs holding a dominant position. In 2024, photosensitizer drugs accounted for 75.4% of the segmental share, underscoring their crucial role in PDT procedures. These drugs, when activated by specific wavelengths of light, target and destroy abnormal cells with precision, making them indispensable to the therapy. Their dominance is attributed to ongoing advancements in drug formulations, resulting in improved efficacy, reduced side effects, and better tissue-specific targeting.

Additionally, photosensitizer drugs are widely used across a range of medical applications, including oncology, dermatology, and ophthalmology, further strengthening their market position. The increasing prevalence of cancer and other chronic diseases has also contributed to the growing demand for photosensitizer drugs. This segment’s growth is further supported by extensive research and development efforts to enhance drug performance and expand PDT’s clinical applications, ensuring sustained market leadership.

Photodynamic Therapy Market, Product Type Analysis, 2020-2024 (US$ Billion)

Application Analysis

In 2024, the cancer segment accounted for 42.9% of the revenue share in the global photodynamic therapy (PDT) market and is projected to grow at a CAGR of 7.1% during the forecast period. PDT is widely utilized in oncology due to its precision in selectively targeting cancer cells while minimizing damage to healthy tissues. It has demonstrated effectiveness in treating various cancers, including skin, esophageal, lung, and head and neck cancers.

• For instance, porfimer sodium (Photofrin) is FDA-approved for the treatment of esophageal and non-small cell lung cancers. Clinical studies have shown that PDT can significantly reduce tumor size and improve survival rates in these conditions.
• According to the World Health Organization (WHO), 2022 saw an estimated 20 million new cancer cases and 9.7 million cancer-related deaths, with 53.5 million people living within five years of a cancer diagnosis. The American Cancer Society highlights that PDT with Photofrin is particularly effective in early-stage lung cancer, providing a minimally invasive alternative to surgical intervention.

Furthermore, in 2024, the acne segment accounted for 19.1% of the revenue share in the global photodynamic therapy (PDT) market and is projected to grow at a CAGR of 8.7% during the forecast period. PDT has become a widely accepted treatment in dermatology for moderate to severe acne. Aminolevulinic acid (ALA), a commonly used photosensitizer in acne therapy, accumulates in sebaceous glands and is activated by blue or red light to generate reactive oxygen species, effectively reducing acne lesions. Clinical studies have demonstrated significant outcomes, with some patients experiencing up to a 70% reduction in acne lesion counts.

• The Omnilux™ LED system has proven successful in acne treatment, offering a non-invasive option with minimal side effects. In a GCP/ICH-compliant study, all participants showed positive treatment responses, with a 73% reduction in inflammatory lesions observed between 8 and 16 weeks, underscoring the efficacy of PDT in managing acne.

Photodynamic Therapy Market, Application Analysis, 2020-2024 (US$ Billion)

End-User Analysis

In 2024, the Hospitals segment dominated the end-user segment by gathering the market share of 48.5%. Hospitals represent a primary end-user segment for PDT, offering comprehensive healthcare services, including advanced medical treatments and procedures. PDT in hospitals is utilized for a wide range of conditions, including cancer, dermatological issues, and ophthalmological diseases. Hospitals frequently use PDT for treating cancers such as esophageal, lung, and head and neck cancers. The availability of advanced equipment and specialized medical staff allows for precise and effective PDT treatments.

Moreover, hospitals often participate in clinical trials and research studies, contributing to the development of new PDT protocols and enhancing the evidence base for its efficacy. The comprehensive care environment in hospitals allows for the management of potential side effects and complications associated with PDT, providing a safe and controlled setting for patients.

However, the high cost of PDT equipment and the need for specialized training can be challenges. Despite these challenges, the integration of PDT in hospital settings is expected to grow, driven by advancements in technology and increasing recognition of PDT’s benefits in cancer and dermatological treatments.

Photodynamic Therapy Market, End-User Analysis, 2020-2024 (US$ Billion)

Key Market Segments

By Type

• Photosensitizer Drugs
  • Aminolevulinic Acid
  • Porphyrin Derivatives
  • Chlorines
  • Others (Tookad (Padeliporfin), Hypericin,HPPH)
• Devices
  • Disposable Fiber Optic Light Delivery Devices (DFOLDD)
  • Diode Laser
  • Others (LED, Lamps)

By Application

• Cancer
• Acne
• Psoriasis
• Actinic Keratosis
• Other Application

By End-User

• Hospitals
• Cosmetics & Dermatology Clinics
• Cancer Treatment Centers
• Research Institutions

Drivers

Increasing Awareness and Adoption of Minimally Invasive Therapies

Photodynamic therapy (PDT) offers a less invasive treatment option for various conditions, including certain cancers and infectious disorders such as bacterially infected wounds, acne vulgaris, viral warts caused by human papillomavirus, and cutaneous leishmaniasis. The growing awareness and adoption of minimally invasive therapies are key drivers of the PDT market.

Patients and healthcare providers increasingly prefer minimally invasive treatments due to their benefits, such as shorter recovery times, reduced risk of complications, and improved patient comfort. PDT’s targeted approach, which minimizes damage to healthy tissues, aligns well with these preferences, making it a popular choice across multiple medical fields.

Products like Levulan® Kerastick®, combined with blue light illumination, have demonstrated success in the U.S. for treating actinic keratosis, delivering effective results with excellent cosmetic outcomes. As awareness grows and clinical outcomes reinforce the benefits of minimally invasive procedures, the adoption of PDT continues to rise. This trend reflects a broader shift in healthcare towards treatments that prioritize efficacy and patient well-being while minimizing physical trauma.

Restrains

Side Effects and Safety Concerns

Although photodynamic therapy (PDT) is a minimally invasive treatment, it is not without side effects and safety concerns, which can pose challenges to its market growth. Common side effects include pain, swelling, and redness at the treatment site, which can cause discomfort and require additional medical attention.

In more severe cases, patients may experience blistering, peeling, or even infections, potentially leading to dissatisfaction and hesitancy to pursue further PDT treatments. Long-term safety concerns, especially with repeated treatments in sensitive areas such as the eyes or internal organs, further contribute to patient and provider apprehension. These issues can discourage patients from choosing PDT despite its therapeutic advantages over more invasive options.

To address these challenges, the development of advanced treatment protocols, effective pain management strategies, and comprehensive patient education is essential. According to the National Cancer Institute, such measures could significantly reduce side effects and alleviate patient concerns, fostering greater acceptance of PDT. However, until these improvements are universally adopted, safety concerns and adverse effects will remain significant restraints on market expansion..

Opportunities

Technological Advancements is Staging Growth Opportunities

The integration of nanotechnology with photodynamic therapy (PDT) offers a promising approach to treating psoriasis, a chronic inflammatory skin condition marked by rapid skin cell proliferation and immune dysregulation. While traditional PDT has proven effective in managing psoriasis, incorporating nanotechnology could enhance its therapeutic outcomes and reduce associated side effects. This approach represents an innovative frontier in psoriasis treatment, focusing on the benefits, recent advancements, and future research opportunities.

Nanotechnology significantly improves the delivery of photosensitizers, key components of PDT. Nanoparticles can encapsulate photosensitizers, enhancing their stability, protecting them from degradation, and improving bioavailability. Additionally, these nanoparticles enable controlled and sustained release of photosensitizers at the target site, ensuring optimal therapeutic concentrations.

Various nanoparticles, including liposomes, polymeric nanoparticles, and gold nanoparticles, have been investigated for delivering photosensitizers such as aminolevulinic acid (ALA) and methyl aminolevulinate (MAL). For example, liposome-encapsulated ALA penetrates deeper into psoriatic plaques, allowing more effective light activation and reducing treatment frequency. Studies indicate these formulations improve photosensitizer uptake by keratinocytes, resulting in more efficient PDT outcomes.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the global photodynamic therapy (PDT) market. Economic conditions, such as inflation, currency fluctuations, and healthcare funding disparities, directly impact the affordability and accessibility of PDT treatments, particularly in low- and middle-income countries. Limited healthcare budgets in these regions can slow the adoption of innovative PDT technologies despite their therapeutic potential.

Geopolitical tensions, trade restrictions, and regulatory disparities between nations also pose challenges to the global distribution of PDT products. For instance, disruptions in the global supply chain due to political conflicts or sanctions can hinder the availability of critical components like photosensitizers and light-based devices.

On the positive side, increased government investments in healthcare infrastructure and international collaborations for cancer and chronic disease treatment drive market growth. Favorable trade agreements and harmonized regulations can enhance cross-border accessibility. Addressing these macroeconomic and geopolitical challenges is essential to ensure equitable access and sustained growth in the PDT market.

Trends

The global photodynamic therapy (PDT) market is experiencing notable trends driven by technological advancements, growing awareness, and expanding applications in various medical fields. A key trend is the development of next-generation photosensitizers with improved targeting capabilities, reduced side effects, and enhanced therapeutic efficacy. These innovations are broadening the scope of PDT beyond oncology, enabling its use in dermatology, ophthalmology, and infectious disease treatments.

The integration of nanotechnology into PDT is another transformative trend. Nanoparticles enhance photosensitizer delivery, stability, and bioavailability, enabling more precise and efficient treatments for conditions like psoriasis and cancer. Advancements in light delivery systems, including portable LED devices and lasers, further improve treatment accuracy and patient convenience.

Increasing awareness of minimally invasive therapies has driven patient and healthcare provider interest in PDT. Additionally, supportive government initiatives, favorable reimbursement policies, and strategic collaborations between industry players are boosting market growth. These trends collectively highlight a dynamic future for the PDT market.

Regional Analysis

North America Dominates the Global Photodynamic Therapy Market

In 2024, North America led the Global Erectile Dysfunction Drugs Market with a 36.1% share and is projected to retain its dominance through the forecast period. Similarly, the Photodynamic Therapy (PDT) market in North America is witnessing strong growth, driven by advancements in medical technology and a rising prevalence of skin cancers and dermatological conditions. The United States plays a key role in this growth due to its advanced healthcare infrastructure and significant investments in research and development.

Prominent U.S. healthcare institutions, such as the Mayo Clinic and Memorial Sloan Kettering Cancer Center, have adopted PDT for treating conditions like actinic keratosis, basal cell carcinoma, and early-stage esophageal and lung cancers. These facilities exemplify the therapy’s effectiveness as a minimally invasive treatment with fewer side effects.

In Canada, PDT adoption is rising due to favorable government policies and increasing awareness among healthcare providers and patients. Health Canada’s approval of photosensitizers like porfimer sodium (Photofrin) has accelerated PDT acceptance. Institutions like the Princess Margaret Cancer Centre in Toronto lead PDT research and clinical applications, particularly for head and neck cancers, further supporting market growth through international collaborations.

Photodynamic Therapy Market, Regional Analysis, 2020-2024 (US$ Billion)

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The Photodynamic Therapy (PDT) market is marked by a dynamic competitive landscape driven by technological innovation, regulatory frameworks, and the efforts of leading players striving for market dominance. PDT, a minimally invasive treatment using photosensitizing agents activated by light to target and destroy abnormal cells, has gained traction in fields like oncology, dermatology, and ophthalmology.

Key companies such as Biofrontera AG and Theralase Technologies Inc. are at the forefront, offering extensive PDT product portfolios. These players capitalize on strong R&D capabilities and strategic collaborations to develop advanced photosensitizers, light sources, and delivery systems, thereby improving treatment outcomes. Partnerships with healthcare institutions and research bodies support clinical trials and broaden market penetration, further solidifying their positions.

Mergers and acquisitions are also common, enabling companies to diversify offerings, expand geographic presence, and enhance technological expertise. Regulatory frameworks play a crucial role, ensuring product safety and efficacy, thereby building consumer trust and facilitating market growth. Cutting-edge advancements, including next-generation photosensitizers, targeted delivery mechanisms, and fluorescence imaging technologies, are shaping the market’s future and driving its expansion.

Recent Developments

• In February 2023, Bausch + Lomb and Modulight, a biomedical laser company, received FDA approval for the ML6710i photodynamic laser. This approval allows its equivalent use with Bausch + Lomb’s VISUDYNE for photodynamic therapy (PDT) in treating predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration (AMD).
• In June 2022, LUMIBIRD established a new subsidiary in Mumbai named Lumibird Medical India. The primary objective of this venture is to drive the sales of Quantel Medical and Ellex products in the Indian market. Lumibird Medical India will focus on offering a diverse array of ophthalmic lasers, ultrasound platforms and cutting-edge equipment designed for both diagnosis and treatment purposes. This expansion reflects LUMIBIRD’s commitment to strengthening its footprint in India and delivering advanced medical technologies to the healthcare sector in the region.
• In March 2021, Boston Scientific unveiled a definitive agreement with Baring Private Equity Asia (BPEA) for the acquisition of the worldwide surgical business of Lumenis LTD. This segment of Lumenis specializes in advanced laser systems, fibers, and accessories utilized in urology and otolaryngology procedures.

Top Key Players in the Photodynamic Therapy Market

• Sun Pharmaceutical Industries Ltd.
• Galderma Laboratories, L.P.
• LUMIBIRD Medical
• Biofrontera AG
• Excel Lasers Limited
• Modulight Corporation
• Candela Medical
• Kernel Medical Equipment Co, Ltd.
• Theralase Technologies Inc.

Report Scope